News

Earlier this month, ValiRx Plc, a life science company focused on early-stage cancer therapeutics and women’s health, announced a new 12-month agreement with Stingray Bio Limited (“Stingray”), placing its wholly owned subsidiary,…

Inaphaea is pleased to announce the execution of an exclusive licence agreement with UK-based Dominion Biotech Ltd for Inaphaea’s PredictRx® platform. PredictRx is a personalised cancer screening service whereby a patient’s tumour…

Life science innovation company ValiRx has announced the appointment of a Director of Research and expanded the lab team of its research subsidiary, Inaphaea BioLabs. Michelle Barnard joins ValiRx to head up…

In December, Roy took part in a two-week internship where he was able to gain valuable experience in the Inaphaea labs.  During his internship Roy was able to draw on the skills…

Inaphaea BioLabs has grown significantly since it was established in 2023. We have made great strides in commercialising our patient derived cell (PDC) bank and now offer cells for purchase and testing…

Inaphaea is pleased to confirm it is collaborating on a project using funds from The Open University’s Higher Education Innovation Fund (HEIF) to characterise the subtype and drug sensitivity of up to 12…

This news round-up covers our latest news and updates from September and October. It has been a busy month for Inaphaea, with our parent company ValiRx signing several agreements with CROs and…

Inaphaea BioLabs’ collaboration partner Inspiralis is a leading biotech specialising in DNA modifying enzymes and their substrates. The company supports preclinical development of anti-infective and anti-cancer compounds, either through the supply of…